Provided by Tiger Fintech (Singapore) Pte. Ltd.

uniQure NV

12.81
-0.3400-2.59%
Post-market: 12.860.0500+0.39%17:38 EDT
Volume:1.58M
Turnover:20.38M
Market Cap:701.08M
PE:-2.93
High:13.30
Open:13.25
Low:12.73
Close:13.15
Loading ...

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More

Zacks
·
11 Dec 2024

RBC Raises Price Target on uniQure to $20 From $14, Keeps Outperform, Speculative Risk

MT Newswires Live
·
11 Dec 2024

uniQure price target raised to $44 from $26 at Leerink

TIPRANKS
·
11 Dec 2024

U.S. RESEARCH ROUNDUP-ICU Medical, Lennar Corp, Sweetgreen

Reuters
·
11 Dec 2024

Uniqure Nv : Leerink Partners Raises Target Price to $44 From $26

THOMSON REUTERS
·
11 Dec 2024

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
11 Dec 2024

UniQure Gets Rating Upgrade From Wells Fargo After Agreement With FDA -- Shares Continue Rally

MT Newswires Live
·
11 Dec 2024

Wells Fargo Upgrades uniQure to Overweight From Equalweight, $35 Price Target

MT Newswires Live
·
11 Dec 2024

Wells upgrades uniQure on ‘high likelihood of success’ in Huntington’s

TIPRANKS
·
11 Dec 2024

uniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Stock Track | uniQure Soars 93.7% as FDA Agrees to Accelerated Approval Pathway for Huntington's Disease Gene Therapy

Stock Track
·
10 Dec 2024

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Dow Jones
·
10 Dec 2024

uniQure Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
10 Dec 2024

Dow Falls 150 Points; Oracle Posts Downbeat Results

Benzinga
·
10 Dec 2024

Stifel says FDA alignment on accelerated path ‘looks like best case’ for uniQure

TIPRANKS
·
10 Dec 2024

UniQure Says Aligned With FDA on Approval Pathway for Huntington's Disease Drug; Shares Jump

MT Newswires Live
·
10 Dec 2024

Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics

TIPRANKS
·
10 Dec 2024

Uniqure Announces Alignment With FDA On Accelerated Approval Pathway For AMT-130 In Huntington’S Disease

T-Reuters
·
10 Dec 2024

U.S.-Listed Shares of Uniqure up 76% Premarket After Reaching Agreement With FDA on Development Plan for Huntington’s Disease Therapy

THOMSON REUTERS
·
10 Dec 2024